SATB2是成骨细胞分化的敏感但不特异的标记

目的探讨SATB2免疫组织化学表达在原发性骨肿瘤病理鉴别诊断中的意义。方法收集65例骨肉瘤、9例骨母细胞瘤、39例软骨肉瘤、10例内生软骨瘤、9例软骨母细胞瘤、9例软骨黏液样纤维瘤、10例纤维结构不良、9例骨性纤维结构不良、8例动脉瘤样骨囊肿、12例骨巨细胞瘤、9例脊索瘤、7例未分化多形性肉瘤、3例纤维肉瘤,采用EnVision两步法进行免疫组织化学染色检测SATB2在这些肿瘤中表达的情况。结果 100%的骨肉瘤、骨母细胞瘤、骨巨细胞瘤、动脉瘤样骨囊肿、纤维结构不良、骨性纤维结构不良表达STAB2;软骨肉瘤阳性比为15/39,软骨母细胞瘤阳性比为1/3,未分化多形性肉瘤阳性比为5/8;其余肿瘤均不表达STAB2。结论 SATB2是成骨细胞敏感但不特异的标记,对原发性骨肿瘤中成骨性肉瘤与非成骨性肉瘤的鉴别诊断意义有限。     

TRF1、TRF2和POT1基因mRNA在前列腺癌组织中的表达

目的:探究端粒重复序列结合蛋白质1(TRF1)、TRF2和端粒保护蛋白(POT1)基因mRNA在前列腺癌(PCa)组织中的表达。方法:收集46例PCa患者肿瘤中心组织(中心组织组)和35例前列腺增生(BPH)患者BPH组织(BPH组织组),提取总RNA,逆转录成cDNA,采用定量PCR测定TRF1、TRF2和POT1在中心组织组和BPH组织基因mRNA的表达,采用基因mRNA所得CT值与β-actin mRNA所得CT值之差(△CT值)表示,并进行差异性分析。结果:中心组织组TRF1的△CT值高于BPH组织组,差异有统计学意义(Z=-3.469,P=0.001);TRF2的△CT值分别为8.49(5.75,10.21)和8.16(6.28,9.75),差异无统计学意义(Z=-1.719,P=0.086);中心组织组POT1的△CT值高于BPH组织组,差异有统计学意义(t=-18.48,P=0.000)。结论:TRF1和POT1在PCa肿瘤组织中的表达升高,说明TRF1和POT1的高表达可能与PCa的发生和发展有关,但TRF2在PCa肿瘤中心组织和BPH组织中的表达没有表现出差异,有待进一步研究。     

端粒长度及端粒酶活性与儿童先天性心脏病发病机制的相关性研究

目的:探讨不同年龄儿童外周血白细胞端粒长度及端粒酶活性与儿童先心病发病机制的相关性.方法:采用实时荧光定量PCR检测先天性心脏病2个年龄组及健康受试者外周血白细胞的端粒长度及hTERT mRNA(端粒酶催化亚基).比较相同年龄的先天性心脏病与健康受试者外周血白细胞的端粒长度及hTERT mRNA差异,并比较不同年龄组间外周血白细胞的端粒长度及hTERT mRNA差异.结果:先天性心脏组3-6岁组的受检者及健康受试者3-6岁组平均外周血白细胞端粒(1.63± 0.61)长于先天性心脏组7-10岁组的受检者及健康受试者7-10岁组(1.36± 0.46)(t=1 1.37,P＜0.05);各组均无端粒酶表达.结论:外周血白细胞的端粒长度随着年龄的增长而缩短.端粒酶活性与先天性心脏病发病并无直接相关性.     

骨肉瘤中P53及P21WAF1表达的生物学意义

应用免疫组化SP法观察34例骨肉瘤中P53及P21WAF1的表达情况,探讨P53及P21WAF1表达与骨肉瘸临床病理学特征之间的关系,分析P53和P21WAF1在骨肉瘤中的作用及其相关性。结果可见,在34例骨肉瘤中,18例表达P53,阳性表达率52.94%;12例表达P21WAF1,阳性表达率35.29%。P53阳性表达与性别、肿瘤分化及是否转移复发有关(P<0.05),P21WAF1与肿瘤分化有关(P<0.01)。P53在中、低分化骨肉瘤中阳性表达率较高,而在高分化骨肉瘤中阳性表达率较低(70%、28.57%);P21WAF1在高分化骨肉瘤中阳性表达率较高,而在中、低分化骨肉瘤阳性表达率较低(85.71%、0%)。P53及P21WAF1表达呈负相关性(r=-0.537,P=0.001)。在骨肉瘤组织中P53表达上调及P21WAF1表达下调与骨肉瘤的恶性进展有关。     

端粒植入胃癌7901细胞对细胞生长、端粒和端粒酶的影响

研究外源端粒片段植入胃癌7901细胞后对细胞生长、端粒长度和端粒酶活性的影响.采用lipofectTM2000介导的转染方式,将含有端粒片段质粒pSXneo-1.6-T2AG3转染胃癌细胞SGC7901,PCR在基因水平上鉴定外源性端粒片段的植入后,采用TRAP法检测转染细胞端粒酶活性变化,TRF法检测转染细胞端粒长度变化,MTT法检测细胞生长曲线,RT-PCR测定转染细胞hTERT表达变化.染色体核型分析细胞染色体变化.结果显示端粒片段成功导入SGC7901细胞后获得稳定的细胞株,端粒片段植入后细胞生长变慢,端粒长度延长不明显,端粒酶活性明显降低,hTERT mRNA表达水平下降,核型分析显示转染前后细胞染色体数目无明显变化.实验成功将携带了1600 bp端粒TTAGGG重复序列的真核表达载体pSX-T2AG3-neo稳定转染至人胃癌7901细胞中,端粒植入降低细胞端粒酶的活性和下调端粒酶活性亚单位hTERT的表达,但对端粒长度无明显影响.     

亚硒酸钠对肝细胞L-02端粒酶活性和端粒长度的作用

通过研究硒对端粒酶活性和端粒长度的作用 ,探讨硒抗衰老的生物学机制。实验以人肝细胞株L 0 2为研究对象 ,分别补充 0 .5和 2 .5 μmol L亚硒酸钠 ,采用端粒重复序列扩增 焦磷酸根酶联发光法、逆转录聚合酶链式反应法及流式荧光原位杂交法 ,分别检测细胞的端粒酶活性、人端粒酶逆转录酶催化亚基基因 (hTERT)的表达及端粒长度的变化。结果表明 :常规培养的肝细胞株L 0 2的端粒酶活性和hTERT基因表达水平均较低。补充 0 .5和2 .5 μmol L亚硒酸钠三周后细胞生长状况良好、端粒酶活性和hTERT基因表达水平显著性增高 ,且呈一定的剂量 效应关系。细胞补充亚硒酸钠四周后端粒长度显著增长。说明营养浓度的亚硒酸钠可通过提高端粒酶活性和增长端粒长度来减缓L 0 2肝细胞衰老、延长细胞寿命。     

外周血单核细胞端粒长度和端粒酶hTERT 活性在心力衰竭中的变化研究

目的:探讨心力衰竭患者外周血单核细胞端粒长度和端粒酶h TERT活性在心衰发生进程中的变化情况和意义。方法:按照筛选要求选择患者,根据入选标准分为心衰组(49例)和非心衰组(44例)。记录患者的年龄、性别、生活习惯及疾病情况,超声检测患者心脏功能,测量左心室舒张末内径(LVEDD)、左心室射血分数(LVEF)。在不同时间点,抽取外周血分离单核细胞,用PCR方法检测端粒长度和端粒酶h TERT活性。结果:对照组比较,心衰组患者心脏左室舒张末内径明显增加,射血分数明显降低(P0.05);在第1、7天,心衰组患者外周血单核细胞端粒长度较对照组明显缩短、端粒酶h TERT活性明显增强。第7天较同组第1天端粒长度有所增加,端粒酶h TERT活性有所减低,但与对照组相比,端粒长度显著缩短,端粒酶h TERT显著增高(P0.05)。结论:心力衰竭后患者端粒长度和端粒酶h TERT活性明显变化,并随心衰发病具有一定波动,提示端粒和端粒酶可能参与了心衰发展进程。     

端粒结合蛋白TRF2的研究进展

端粒DNA结合蛋白TRF2(TTAGGG repeat binding factor-2)以二聚体形式通过Myb结构域与端粒重复序列TTAGGG结合,并与TRF1、TIN2、Rap1、TINT1及POT1蛋白组成Shelterin蛋白复合物,协同在端粒动态平衡维持过程中起关键作用,进而影响整个基因组的稳定性。此外,TRF2在细胞DNA损伤应答过程中可能发挥重要作用。本文将对TRF2结构和功能研究的最新进展进行综述。     

Oncogene alterations in primary,recurrent, and metastatic human bone tumors

We investigated the structure and the expression of various oncogenes in three of the most common human bone tumors—osteosarcoma (36 samples from 34 patients), giant cell tumor (10 patients), and chondrosarcoma (18 patients)—in an attempt to identify the genetic alterations associated with these malignancies. Alterations of RB and p53 were detected only in osteosarcomas. Alterations of c-myc, N-myc, and c-fos were detected in osteosarcomas and giant cell tumors. Ras alterations (H-ras, Ki-ras, N-ras) were rare. Chondrosarcomas did not contain any detectable genetic alterations. Our results suggest that alterations of c-myc, N-myc, and c-fos oncogenes occur in osteosarcomas, in addition to those previously described for the tumor suppressor genes RB and p53. Moreover, statistical analyses indicate that c-fos alterations occur more frequently in osteosarcoma patients with recurrent or metastatic disease. © 1996 Wiley-Liss, Inc.     

Suppression of hPOT1 in diploid human cells results in an hTERT-dependent alteration of telomere length dynamics

POT1 is a 3' telomeric single-stranded overhang binding protein that has been implicated in chromosome end protection, the regulation of telomerase function, and defining the 5' chromosome terminus. In human cancer cells that exhibit constitutive hTERT activity, hPOT1 exerts control over telomere length. Primary human fibroblasts express low levels of catalytically active hTERT in an S-phase-restricted manner that fails to counteract telomere attrition with cell division. Here, we show that diploid human fibroblasts in which hPOT1 expression has been suppressed harbor telomeres that are longer than control cells. This difference in telomere length delays the onset of replicative senescence and is dependent on S-phase-restricted hTERT expression. These findings are consistent with the view that hPOT1 promotes a nonextendable telomere state resistant to extension by S-phase-restricted telomerase. Manipulating this function of hPOT1 may thus hasten the cytotoxic effects of telomerase inhibition.     

PTOP interacts with POT1 and regulates its localization to telomeres

Telomere maintenance has been implicated in cancer and ageing, and requires cooperation between a multitude of telomeric factors, including telomerase, TRF1, TRF2, RAP1, TIN2, Tankyrase, PINX1 and POT1 (refs 1-12). POT1 belongs to a family of oligonucleotide-binding (OB)-fold-containing proteins that include Oxytricha nova TEBP, Cdc13, and spPot1, which specifically recognize telomeric single-stranded DNA (ssDNA). In human cells, the loading of POT1 to telomeric ssDNA controls telomerase-mediated telomere elongation. Surprisingly, a human POT1 mutant lacking an OB fold is still recruited to telomeres. However, the exact mechanism by which this recruitment occurs remains unclear. Here we identify a novel telomere protein, PTOP, which interacts with both POT1 and TIN2. PTOP binds to the carboxyl terminus of POT1 and recruits it to telomeres. Inhibition of PTOP by RNA interference (RNAi) or disruption of the PTOP-POT1 interaction hindered the localization of POT1 to telomeres. Furthermore, expression of the respective interaction domains on PTOP and POT1 alone extended telomere length in human cells. Therefore, PTOP heterodimerizes with POT1 and regulates POT1 telomeric recruitment and telomere length.     

In Vivo Stoichiometry of Shelterin Components

Human telomeres bind shelterin, the six-subunit protein complex that protects chromosome ends from the DNA damage response and regulates telomere length maintenance by telomerase. We used quantitative immunoblotting to determine the abundance and stoichiometry of the shelterin proteins in the chromatin-bound protein fraction of human cells. The abundance of shelterin components was similar in primary and transformed cells and was not correlated with telomere length. The duplex telomeric DNA binding factors in shelterin, TRF1 and TRF2, were sufficiently abundant to cover all telomeric DNA in cells with short telomeres. The TPP1·POT1 heterodimer was present 50–100 copies/telomere, which is in excess of its single-stranded telomeric DNA binding sites, indicating that some of the TPP1·POT1 in shelterin is not associated with the single-stranded telomeric DNA. TRF2 and Rap1 were present at 1:1 stoichiometry as were TPP1 and POT1. The abundance of TIN2 was sufficient to allow each TRF1 and TRF2 to bind to TIN2. Remarkably, TPP1 and POT1 were ∼10-fold less abundant than their TIN2 partner in shelterin, raising the question of what limits the accumulation of TPP1·POT1 at telomeres. Finally, we report that a 10-fold reduction in TRF2 affects the regulation of telomere length but not the protection of telomeres in tumor cell lines.     

Telomere maintenance through spatial control of telomeric proteins

The six human telomeric proteins TRF1, TRF2, RAP1, TIN2, POT1, and TPP1 can form a complex called the telosome/shelterin, which is required for telomere protection and length control. TPP1 has been shown to regulate both POT1 telomere localization and telosome assembly through its binding to TIN2. It remains to be determined where such interactions take place and whether cellular compartmentalization of telomeric proteins is important for telomere maintenance. We systematically investigated here the cellular localization and interactions of human telomeric proteins. Interestingly, we found TIN2, TPP1, and POT1 to localize and interact with each other in both the cytoplasm and the nucleus. Unexpectedly, TPP1 contains a functional nuclear export signal that directly controls the amount of TPP1 and POT1 in the nucleus. Furthermore, binding of TIN2 to TPP1 promotes the nuclear localization of TPP1 and POT1. We also found that disrupting TPP1 nuclear export could result in telomeric DNA damage response and telomere length disregulation. Our findings highlight how the coordinated interactions between TIN2, TPP1, and POT1 in the cytoplasm regulate the assembly and function of the telosome in the nucleus and indicate for the first time the importance of nuclear export and spatial control of telomeric proteins in telomere maintenance.     

端粒保护蛋白

端粒保护蛋白（pmtection of telomere 1,PoT1）是存在于人和裂殖酵母的端粒相关蛋白,特异性地与端粒单链DNA相结合。人POT1基因位于7号染色体上,由22个外显子组成,其中4个外显子属于跳跃外显子,可形成5个剪接变异体。POT1的功能在于维持端粒的稳定,通过TRF1．TIN2．PIP1-POT通路调节端粒长度。     

端粒保护蛋白1(POT1)的研究进展

端粒保护蛋白1(protection of telomeres 1,POT1)几乎存在于所有真核生物中,是一种高度保守表达的蛋白质,它与一系列相关的端粒结合蛋白共同参与保护端粒的结构和功能。随着近年来研究的深入,POT1与端粒的结合特点以及保护端粒的机制有了进一步的完善。此外,POT1对端粒长度的调节方式以及与肿瘤的发生、发展和细胞凋亡等关系也呈现出多样化。结合近几年的研究文献,对POT1的功能以及与其它相关蛋白的作用加以综述。     

Human protection of telomeres 1 (POT1) is a negative regulator of telomerase activity in vitro

The telomeric single-strand DNA binding protein protection of telomeres 1 (POT1) protects telomeres from rapid degradation in Schizosaccharomyces pombe and has been implicated in positive and negative telomere length regulation in humans. Human POT1 appears to interact with telomeres both through direct binding to the 3' overhanging G-strand DNA and through interaction with the TRF1 duplex telomere DNA binding complex. The influence of POT1 on telomerase activity has not been studied at the molecular level. We show here that POT1 negatively effects telomerase activity in vitro. We find that the DNA binding activity of POT1 is required for telomerase inhibition. Furthermore, POT1 is incapable of inhibiting telomeric repeat addition to substrate primers that are defective for POT1 binding, suggesting that in vivo, POT1 likely affects substrate access to telomerase.     

Telomestatin-induced telomere uncapping is modulated by POT1 through G-overhang extension in HT1080 human tumor cells

Telomestatin is a potent G-quadruplex ligand that interacts with the 3' telomeric overhang, leading to its degradation, and induces a delayed senescence and apoptosis of cancer cells. POT1 and TRF2 were recently identified as specific telomere-binding proteins involved in telomere capping and t-loop maintenance and whose interaction with telomeres is modulated by telomestatin. We show here that the treatment of HT1080 human tumor cells by telomestatin induces a rapid decrease of the telomeric G-overhang and of the double-stranded telomeric repeats. Telomestatin treatment also provokes a strong decrease of POT1 and TRF2 from their telomere sites, suggesting that the ligand triggers the uncapping of the telomere ends. The effect of the ligand is associated with an increase of the gamma-H2AX foci, one part of them colocalizing at telomeres, thus indicating the occurrence of a DNA damage response at the telomere, but also the presence of additional DNA targets for telomestatin. Interestingly, the expression of GFP-POT1 in HT1080 cells increases both telomere and G-overhang length. As compared with HT1080 cells, HT1080GFP-POT1 cells presented a resistance to telomestatin treatment characterized by a protection to the telomestatin-induced growth inhibition and the G-overhang shortening. This protection is related to the initial G-overhang length rather than to its degradation rate and is overcome by increased telomestatin concentration. Altogether these results suggest that telomestatin induced a telomere dysfunction in which G-overhang length and POT1 level are important factors but also suggest the presence of additional DNA sites of action for the ligand.     

POT1b protects telomeres from end-to-end chromosomal fusions and aberrant homologous recombination

POT1 (protection of telomere 1) is a highly conserved single-stranded telomeric binding protein that is essential for telomere end protection. Here, we report the cloning and characterization of a second member of the mouse POT family. POT1b binds telomeric DNA via conserved DNA binding oligonucleotide/oligosaccharide (OB) folds. Compared to POT1a, POT1b OB-folds possess less sequence specificity for telomeres. In contrast to POT1a, truncated POT1b possessing only the OB-folds can efficiently localize to telomeres in vivo. Overexpression of a mutant Pot1b allele that cannot bind telomeric DNA initiated a DNA damage response at telomeres that led to p53-dependent senescence. Furthermore, a reduction of the 3' G-rich overhang, increased chromosomal fusions and elevated homologous recombination (HR) were observed at telomeres. shRNA mediated depletion of endogenous Pot1b in Pot1a deficient cells resulted in increased chromosomal aberrations. Our results indicate that POT1b plays important protective functions at telomeres and that proper maintenance of chromosomal stability requires both POT proteins.